

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 31 MAY 2024

POLL RESULTS OF THE EGM

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 7 May 2024 (the “**Circular**”) and the notice (the “**Notice**”) of extraordinary general meeting (the “**EGM**”) dated 7 May 2024. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that, all proposed resolutions (save for resolution no. 3) as set out in Notice were passed by way of poll at the EGM held on Friday, 31 May 2024. All Directors attended the EGM in person or by way of video conference.

As at the date of the EGM, the total number of issued Shares was 842,811,911 Shares, and the total number of Shares entitling the holders to attend and vote for or against the resolutions at the EGM was also 842,811,911 Shares. No Shareholder entitled to attend the EGM was required to abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders is required under the Listing Rules to abstain from voting on the resolutions at the EGM. None of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.

The poll results in respect of the resolutions are as follows:

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	(a) To approve the adoption of the 2024 Share Option Scheme (as defined in the circular of the Company dated 7 May 2024 (the “Circular”)); and	273,634,356 (59.81%)	183,888,283 (40.19%)
	(b) To approve the adoption of the Scheme Mandate Limit (as defined in the Circular).	274,943,356 (60.09%)	182,579,283 (39.91%)
2.	Conditional upon the above ordinary resolutions no. 1 being duly passed, to approve the adoption of the Service Provider Sublimit (as defined in the Circular).	273,801,356 (59.84%)	183,721,283 (40.16%)
Special resolution		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
3.	To approve the proposed amendments to the existing memorandum and articles of association of the Company and to adopt the second amended and restated memorandum and articles of association of the Company, and to authorise any one director, registered office provider or company secretary of the Company to do all such acts and things and execute all such documents to effect the same.	321,378,685 (70.24%)	136,143,954 (29.76%)

* *The full text of resolutions no. 1 to no. 3 are set out in the Notice.*

As more than 50% of the votes were cast in favour of each of the ordinary resolutions (resolutions no. 1 to no. 2), such resolutions were duly passed by the Shareholders.

Resolution no. 3 was proposed to ensure that the Company complied with the latest regulatory requirements in relation to the expanded paperless listing regime and the electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the the Listing Rules which took effect from 31 December 2023. The Company notes that 70.24% of votes cast were in favour of resolution no. 3. Nevertheless, resolution no. 3 was not passed as it failed to achieve the three-fourths voting requirement needed to pass it as a special resolution.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

By Order of the Board
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 31 May 2024

As at the date of this announcement, the Board comprises Mr. An Meng and Professor Zhu Quan as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive Directors.